Ibrutinib (IMBRUVICA) to remain on the Cancer Drugs Fund list for the treatment of two types of blood cancer

Janssen is extremely pleased that NHS England has confirmed that Janssen-Cilag International NV’s (Janssen) ibrutinib (IMBRUVICA®) will remain on the Cancer Drugs Fund (CDF) for the treatment… Source link